$PHAS News
Last published 4y ago
- 4y agoPHASPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodeBusiness WireBidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel
- 4y agoPHASPhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business HighlightsBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June
- 4y agoPHASPhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business HighlightsBusiness WireHeld successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commerci
- 4y agoPHASPhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for BentracimabBusiness WirePhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness t
- 4y agoPHASPhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare ConferenceBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will partic
- 4y agoPHASPhaseBio Announces Positive Results from Phase 2b Trial for BentracimabBusiness WireResults presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab
- 4y agoPHASPhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business HighlightsBusiness WireAchieved key clinical milestones for bentracimab program, with positive results from both the completed Phase 2b trial and interim analysis of the ongoing REVERSE-IT global Phase 3 trial Company remains on track to submit Biologics License Applicatio
- 4y agoPHASPhaseBio Pharmaceuticals Announces Bentracimab Manufacturing UpdateBusiness WireManufacturing of bentracimab drug substance and drug product Process Performance Qualification (PPQ) batches has been completed PhaseBio remains on track to submit bentracimab Biologics License Application (BLA) in mid-2022 PhaseBio Pharmaceutical
- 4y agoPHASPhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care ConferenceBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will p
- 4y agoPHASPhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific SessionBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Phase 2b trial of bentracimab, which was
- 4y agoPHASPhaseBio Provides Pemziviptadil (PB1046) Program UpdateBusiness WirePhase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) voluntarily ended early by the Company in order to evaluate existing program data and determine next steps forward Company to reprioritize resources and capital towards successf
- 4y agoPHASStudy to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers - NCT05162131ClinicalTrials.govIncidence and severity of AEs, Incidence of Clinical Laboratory Abnormalities, Vital Sign Measurements - Changes in Diastolic Blood Pressure, (and 82 more...)
- 4y agoPHASPhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM EvidenceBusiness WireResults previously presented in a Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and co-primary endpoint of clinical hemostasis
- 4y agoPHASPhaseBio Names Jonathan Birchall as Chief Commercial OfficerBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief C
- 4y agoPHASPhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening BleedingBusiness WireGlobal Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in gr
- 5y agoPHASPhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business HighlightsBusiness WireAnnounced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of bentracimab Prespecified interim analysis
- 5y agoPHASPhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual MeetingBusiness WirePrespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Ch
- 5y agoPHASPhaseBio Announces Topline Results From Phase 2b Trial for BentracimabBusiness WireTrial achieved primary reversal endpoint in healthy, older volunteers Safety and efficacy profile of bentracimab in the Phase 2b trial consistent with previously completed Phase 1 and Phase 2a trials Interim results from REVERSE-IT Phase 3 trial t
- 5y agoKTRAPHASRLXRVNC+1Thinking about buying stock in Waitr Holdings, RLX Technology, Kintara Therapeutics, Revance Therapeutics, or PhaseBio Pharmaceuticals?PR NewswireNEW YORK, Oct. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WTRH, RLX, KTRA, RVNC, and PHAS. T
- 5y agoPHASPhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021Business WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that REVERSE-IT (Rapid and SustainEd ReVERSal of T
- 5y agoPHASPhaseBio Appoints William D. Humphries to Board of DirectorsBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its boa
- 5y agoABSIPHASAbsci Reports Second Quarter 2021 Financial and Operating ResultsGlobeNewswireVANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and ope
- 5y agoPHASPhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment ConferenceBusiness WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provi
- 5y agoPHASPhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business HighlightsBusiness WireEntered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment mi
- 5y agoPHASPhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of TicagrelorBusiness WireFirst 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focu
- 5y agoPHASPhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for BentracimabBusiness WireEnrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization o
- 5y agoPHASPhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15Business WirePhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will
- 5y agoPHASPhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of BentracimabBusiness WireAgreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab oppo
- 5y agoPHASPhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 ConferenceBusiness WireStudy leveraging the IBM® MarketScan® claims database examined healthcare resource utilization including total healthcare costs and bleeding costs in patients initiating P2Y12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients
- 5y agoPHASPhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific SessionBusiness WireStudy leveraging the IBM® MarketScan® claims database examined bleeding events and rates of surgical procedures in patients initiating P2Y12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y12 inhibitors had a h
- 5y agoPHASPhaseBio Reports First-Quarter 2021 Financial Results and Recent Business HighlightsBusiness WireContinued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public
- 5y agoPHASPhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare ConferenceBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11 ...
- 5y agoPHASPhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the closing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $3.50 per share, including the full ...
- 5y agoPHASPhaseBio Announces Pricing of Public Offering of Common StockBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $3.50 per share. The gross proceeds ...
- 5y agoPHASPhaseBio Announces Proposed Public Offering of Common StockBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day opt ...
- 5y agoPHASPhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business HighlightsBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.
- 5y agoPHASPhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of BentracimabBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the producti ...
- 5y agoPHASPhaseBio Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences. Details of the events are as follows:
- 5y agoPHASPhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021Business WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host a virtual Investor and Analyst Day on March 15, 2021 from 12:00 p.m. to 2:00 p.m. ET. The event will focus on an overview of the bentra ...
- 5y agoPHASPhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of TicagrelorBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, PhaseBio has expanded its pivota ...
- 5y agoPHASPhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World CongressBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a Phase 1b/2a pilot study highlighting three patients who received pemziviptadil (PB1046), the company’s first-in-class, sustai ...
- 6y agoPHASPhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial ResultsBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2020 financial results.
- 6y agoPHASPhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18thBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference ...
- 6y agoPHASPhaseBio Provides Pemziviptadil (PB1046) Program UpdateBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that, after a strategic review of the VANGARD clinical trial that included an assessment of the evolving COVID-19 treatment landscape, feedback from the ...
- 6y agoPHASPhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of TicagrelorBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has expanded its pivotal Phase 3 REVERSE-IT trial for its lead product candidate bentracimab (formerly PB2452) into Canada, where the first patie ...
- 6y agoPHASPhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22nd Annual Global Invest ...
- 6y agoPHASPhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial ResultsBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today provided an update on corporate activities and reported second-quarter 2020 financial results.
- 6y agoPHASPhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 PatientsBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 ...
- 6y agoPHASPhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 PatientsBusiness WireMALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who ...
- 6y agoPHASPhaseBio Reports First Quarter 2020 Financial Results and Recent Business HighlightsBusiness WireMALVERN, Pa & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.